Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12623001019695p
Ethics application status
Submitted, not yet approved
Date submitted
31/08/2023
Date registered
20/09/2023
Date last updated
20/09/2023
Date data sharing statement initially provided
20/09/2023
Type of registration
Prospectively registered

Titles & IDs
Public title
Investigating Novel Pharmacological Treatments for Anorexia Nervosa - A Clinical Trial
Scientific title
A Double-Blinded, 5-Arm, Covariate-Adjusted Adaptive Clinical Trial Evaluating the Efficacy of Novel Pharmacological Agents for the Treatment of Anorexia Nervosa in Individuals Aged 16 and Over
Secondary ID [1] 310512 0
None
Universal Trial Number (UTN)
Trial acronym
AN5
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Anorexia nervosa 331317 0
Condition category
Condition code
Mental Health 328072 328072 0 0
Eating disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
ARM 1:
Drug - Memantine hydrochloride
Dose - 20 mg once daily
Duration - 12 weeks
Mode - Oral tablet

ARM 2:
Drug - Brexpiprazole
Dose - 1 mg once daily
Duration - 12 weeks
Mode - Oral tablet

ARM 3:
Drug - Zinc gluconate
Dose - 228.5 mg once daily
Duration - 12 weeks
Mode - Oral tablet

ARM 4:
Drug - Sodium butyrate
Dose - 300 mg once daily
Duration - 12 weeks
Mode - Oral tablet

Adherence monitoring:
We'll be asking participants of their adherence during the fortnightly catch-up.
We typically ask:
- Have you missed any pills in the last fortnight? If so, how many
- How many pills do you have left?
- If more than 2 pills missed, did you miss these 2 days in a row?
- Record any other details

The fortnightly catch-up will be conducted by the study doctor or nurse. It will either be a brief 5-10 min phone call or completed in conjunction with a visit to the research site (depending on whether the participant is scheduled to visit the research site that week). Participants will also undertake a nutritional assessment with a dietician at baseline. This assessment should take approximately 30 minutes. Further, those participants who are not already receiving external clinical care will be receiving supportive therapy from trained research staff on a fortnightly basis. This will either be a 30 minute phone or Zoom call or completed in conjunction with a visit to the research site, depending on whether the participant is scheduled to visit the research site that week.

Scheduled visits to the research site will take place at Baseline (3 hours), Week 4 (1 hour), Week 8 (1 hour), Week 12. (2.5 hours) There will also be a scheduled follow-up visit to the research site 3 months after having completed the study., which should take approximately 1 hour.

Baseline Visit:
At the Baseline Visit, the following assessments will be conducted:
• The participant will be asked some questions regarding current symptoms of AN, quality of life and readiness to change.
• The participant will be required to complete some cognitive tasks that measure thinking (i.e., memory and attention), and decision-making skills.
• The participant will be asked to fixate on a fixation cross while being measured using an eye tracker.
• A physical examination will be performed by a nurse or the study doctor.
• A nutritional assessment, where we ask questions about dietary intake
At the end of this session, the study medication will be prescribed.

Visits 3 and 4
The participant will be:
• asked questions about mood and symptoms
• asked about experiences of side effects and any adverse events or health problems since last visit
• A physical examination will be performed by a nurse or the study doctor
• A blood test to measure liver, kidney, white blood cell, inflammation, glucose, hormones and levels of calcium, magnesium and phosphate .(25 ml)

Visit 5: Final Treatment Visit
The following assessments will be conducted:
• The participant will be asked some questions regarding current symptoms of AN, quality of life and readiness to change.
• The participant will be asked whether he/she has experienced any side effects or adverse events.
• The participant will be interviewed regarding mood and other symptoms in the past two weeks.
• The participant will be asked questions about your quality of life.
• The participant will be asked to fixate on a fixation cross while being measured using an eye tracker
• A physical examination will be performed by the study doctor.
• If completed at baseline, the participant will be required to complete some cognitive tasks that measure thinking (i.e., memory and attention) skills and decision-making skills .
• Blood tests and a urine and faecal sample will be collected to assess how symptoms affect biological markers in the blood. These will be compared to the blood tests collected at baseline and throughout the study to assess response to the medication.
• A blood test to measure your liver, kidney, white blood cell, inflammation, glucose, hormones and levels of calcium, magnesium, phosphate and zinc (24.5 ml)
• A saliva test to measure your cortisol levels (1 x 5 ml). This will be compared to the saliva samples collected at baseline to assess response to the medication.
• The participant will be asked to provide a stool sample (can be collected at home or in a private space at the research site, depending on preference) to measure butyrate and zinc levels.
• A nutritional assessment,
• Cortisol measures will be evaluated via saliva samples (1x 5mL) This will be compared to the saliva samples collected at baseline to assess your response to the medication.

The supportive therapy will be administered either by a mental health dietician, psychologist or trained research staff. During supportive therapy sessions, we will check in with you to see how the participant is doing. The sessions will be non-judgemental and led by the participant, and will allow us to establish a good therapeutic alliance and identify your strengths.


Intervention code [1] 326905 0
Treatment: Drugs
Comparator / control treatment
Drug - Natvia "sugar" pill
Dose - 1 capsule daily
Duration - 12 weeks
Mode - Oral tablet
Control group
Placebo

Outcomes
Primary outcome [1] 335939 0
Change in eating disorder symptoms as measured by Change in Eating Disorder Symptom Scale (CHEDS)
Timepoint [1] 335939 0
Baseline, 12 weeks after intervention commencement
Primary outcome [2] 335940 0
Change in Body Max Index. Height will be measured using a stadiometer, and weight will be measured using digital scales.
Timepoint [2] 335940 0
Baseline, 12 weeks after intervention commencement
Secondary outcome [1] 426202 0
Change in eating disorder symptoms as measured by the Eating Disorder-15 (ED-15)
Timepoint [1] 426202 0
Baseline, 12 weeks after intervention commencement
Secondary outcome [2] 426203 0
Change in eating disorder symptoms as measured by the Eating Disorder Examination Questionnaire version 6 (EDE-Q).
Timepoint [2] 426203 0
Baseline, 12 weeks after intervention commencement
Secondary outcome [3] 426204 0
Change in clinical impairment as measured by the Clinical Impairment Assessment Questionnaire (CIA).
Timepoint [3] 426204 0
Baseline, 12 weeks after intervention commencement
Secondary outcome [4] 426205 0
Change in body image as measured by the Body Image-Acceptance and Action Questionnaire (BI-AAQ).
Timepoint [4] 426205 0
Baseline, 12 weeks after intervention commencement
Secondary outcome [5] 426206 0
Change in eating attitude as measured by the Disordered Eating Attitude Scale (DEAS).
Timepoint [5] 426206 0
Baseline, 12 weeks after intervention commencement
Secondary outcome [6] 426207 0
Change in eating disorder symptoms as measured by the Munich Eating Disorder Questionnaire.
Timepoint [6] 426207 0
Baseline, 12 weeks after intervention commencement
Secondary outcome [7] 426208 0
Change in eating disorder symptoms as measured by the Eating Pathology Symptoms Inventory (EPSI).
Timepoint [7] 426208 0
Baseline, 12 weeks after intervention commencement
Secondary outcome [8] 426209 0
Change in eating disorder symptoms as measured by the Eating Pathology Symptoms Inventory - Clinician Rated Version (EPSI-CRV).
Timepoint [8] 426209 0
Baseline, 12 weeks after intervention commencement
Secondary outcome [9] 426210 0
Change in fear of food as measured by the Fear of Food Measure.
Timepoint [9] 426210 0
Baseline, 12 weeks after intervention commencement
Secondary outcome [10] 426211 0
Change in self-efficacy as measured by the Eating Disorder Recovery Self-Efficacy Questionnaire (EDRSQ).
Timepoint [10] 426211 0
Baseline, 12 weeks after intervention commencement
Secondary outcome [11] 426212 0
Change in readiness to change as measured by a single question asking "How ready are you to change your eating and weight?" rated on a 10 point Likert scale.
Timepoint [11] 426212 0
Baseline, 12 weeks after intervention commencement

Eligibility
Key inclusion criteria
1. Diagnosis of anorexia nervosa (restrictive or binge-eating/purging subtype), in accordance with the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5).
2. 16 years or older in age.
3. Baseline body mass index (BMI) of equal to or greater than 14
4. Demonstrated capacity to give informed consent.
5. No initiation of therapies targeting AN within the 4 weeks prior to screening. This includes pharmacological and psychological therapies.
6. No increase or initiation of medications with appetite suppressing and/or weight loss effects within the 4 weeks prior to screening.
7. Engagement with a GP at the time of enrolment and over the course of trial participation.
8. Consent for the research team to communicate with the participant’s clinical treatment team in regard to a) Their progress through the trial and b) Communicate clinical deterioration and risks to allow facilitation of appropriate management, where clinically-indicated.
Minimum age
16 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Inability to provide informed consent.
2. Hospitalisation within the 2-months prior to screening for the purpose of managing risk of refeeding or treatment of other medical instability that has a causal link with AN.
3. Physical parameters meeting Criteria for Medical Ward Admission as per the The Royal Australian and New Zealand College of Psychiatrists (RANZCP) Alfred Health Eating Disorder – Inpatient Access and Treatment Pathways Guideline, namely:
a. High refeeding risk;
b. Vital signs as follows:
i. Systolic BP < 80 mmHg;
ii. Postural BP drop > 20 mmHg systolic, > 10 mmHg diastolic;
iii. Heart rate < 40 or > 110;
iv. Postural tachycardia >20bpm
v. Temperature < 35.5°C.
c. ECG changes not overtly benign
d. Blood tests within the preceding 7 days showing:
i. Blood Glucose <3.0 mmol/L
ii. Serum sodium <130 mmol/L
iii. Serum magnesium < 0.6 mmol/L
iv. Serum potassium <3.0 mmol/L
v. Serum phosphate <0.7 mmol/L
vi. Glomerular filtration rate < 60ml/min (Cockroft-Gault)
vii. Albumin <27 g/L
viii. Liver Enzymes ALT > 3 x upper limit of normal
ix. Neutrophils <1.0x109/L
e. GCS <15
4. Participants who are pregnant or breastfeeding
5. Participants who are taking antipsychotic medication. Antipsychotics that are used as needed may be accepted at the clinical judgement of the investigator.
6. Taking equal to or greater than 4 psychotropic medications at the time of screening.
7. Diagnosed with Type I diabetes, hyperthyroidism, Crohn’s disease or other conditions that reduce weight
8. Other clinically significant cardiac, respiratory, renal, oncological or endocrine conditions, or evidence of medical instability, at the clinical judgement of the investigator.
9. Current substance use meeting DSM-5 criteria for severe substance use disorder.
10. Diagnosis of any other mental disorder that is the participant’s primary diagnosis or main mental health syndrome of concern at the time of screening, which may significantly affect psychiatric status and assessed as likely to impact trial participation, at the clinical judgement of the investigator.
11. Use of any investigational procedure (e.g., clinical trial) within 30 days prior to randomisation. In case of exposure to an investigational medicinal product, the investigator must ensure that it is adequately washed out prior to randomisation (at least 30 days or 5 half-lives of the investigational medicinal product, whatever is longer).
12. Participants with severe and enduring anorexia, defined by an illness duration of at least 7 years.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The person who will determine if a subject is eligible for inclusion in the trial will be unaware, when this decision is made, to which group the subject will be allocated. Allocation concealment will be done by contacting the holder of the allocation schedule who will be an independent Monash Alfred Psychiatry Research Centre (MAPrc) staff member.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
If eligible for inclusion, each participant will be randomly assigned to a treatment regimen according to a computer generated pseudo-random code. 1:1:1:1:1 block randomisation utilising randomly permuted blocks of random size will be used to ensure balanced participant numbers in both arms, with randomisation, blinding and medication dispensing performed for this trial by an independent MAPrc staff member. Participants, raters, and clinicians are “blind” as to the medication received.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/12/2023
Actual
Date of last participant enrolment
Anticipated
1/12/2026
Actual
Date of last data collection
Anticipated
1/03/2027
Actual
Sample size
Target
125
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 314715 0
University
Name [1] 314715 0
Monash University
Country [1] 314715 0
Australia
Primary sponsor type
University
Name
Monash University
Address
Faculty of Education Monash University19 Ancora Imparo Way, Clayton Victoria 3800 Australia
Country
Australia
Secondary sponsor category [1] 316687 0
None
Name [1] 316687 0
Address [1] 316687 0
Country [1] 316687 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 313779 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 313779 0
55 Commercial Rd, Melbourne VIC 3004
Ethics committee country [1] 313779 0
Australia
Date submitted for ethics approval [1] 313779 0
06/09/2023
Approval date [1] 313779 0
Ethics approval number [1] 313779 0

Summary
Brief summary
The primary purpose of the study is to investigate the effects of 4 different novel pharmacological treatments in the treatment of anorexia nervosa. We hypothesise that there will be a significant difference in a) improvement in AN symptoms from baseline to end of treatment, and 2) increase in BMI from baseline to end of treatment in the 4 groups receiving pharmacological treatment as compared to the control group.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 129150 0
Prof Jayashri Kulkarni
Address 129150 0
MAPrc & The Li Transformative Hub for Research into Eating Disorders (THRED), Level 4 607 St Kilda Road 3004 Melbourne
Country 129150 0
Australia
Phone 129150 0
+61 03 9076 6564
Fax 129150 0
Email 129150 0
jayashri.kulkarni@monash.edu
Contact person for public queries
Name 129151 0
Dr Eva Gregertsen
Address 129151 0
MAPrc & THRED, Level 4 607 St Kilda Road 3004 Melbourne
Country 129151 0
Australia
Phone 129151 0
+61 3 9076 9802
Fax 129151 0
Email 129151 0
eva.gregertsen@monash.edu
Contact person for scientific queries
Name 129152 0
Dr Eva Gregertsen
Address 129152 0
MAPrc & THRED, Level 4 607 St Kilda Road 3004 Melbourne
Country 129152 0
Australia
Phone 129152 0
+61 3 9076 9802
Fax 129152 0
Email 129152 0
eva.gregertsen@monash.edu

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.